NCT07135453View on ClinicalTrials.gov

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
VaccinePneumococcal Disease
Interventions
BIOLOGICAL

Pneumococcal Vaccine

PCV

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Alabama at Birmingham

OTHER